Transaction #19462 · Form 4 · 0002072013-25-000006
Caris Life Sciences, Inc. · Exercise / conversion · Common Stock
Caris Life Sciences, Inc. · Transacted December 11, 2025 · Filed December 12, 2025
What does this filing report?
An SEC Form 4 filing for Caris Life Sciences, Inc. records an exercise / conversion involving Common Stock on December 11, 2025. The reported quantity was 24,750. The filing date is December 12, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Caris Life Sciences, Inc.
- Company CIK
- 0002019410
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 24,750
- Reported price
- 2.44
- Reference value
- 60,390
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 124,321
- Ownership description
- Not reported
- SEC acceptance time
- Dec 12, 2025, 7:39 PM EST
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Power Luke Thomas ↗
See Remarks
CIK 0002072013
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.
- F2
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.11 to $27.07, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.20, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4
- The stock option is fully vested and exercisable.
Remarks
Senior Vice President, Chief Financial Officer, and Chief Accounting Officer
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.